Related Experiment Video
Updated: May 27, 2026
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Acute lymphoblastic leukemia in adults
1Clinical Hematology Department, Institut Catala d'Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Spain;
Insights
Acute lymphoblastic leukemia (ALL) treatment advances, particularly in adults, involve adapting pediatric regimens and improving supportive care. Minimal residual disease monitoring and targeted therapies offer future hope for better outcomes.
Area of Science:
- Hematology
- Pediatric Oncology
- Clinical Research
Background:
- Acute lymphoblastic leukemia (ALL) is a common childhood cancer, but rare in adults.
- Pediatric ALL treatment advances primarily stem from optimizing existing therapies.
- Recent years have seen improvements in adult ALL outcomes.
Purpose of the Study:
- To review recent advances in the treatment of acute lymphoblastic leukemia (ALL).
- To discuss the application of pediatric regimens in adult ALL.
- To highlight emerging therapeutic strategies and supportive care improvements.
Main Methods:
- Review of current literature on pediatric and adult ALL treatment.
- Analysis of advances in supportive care for stem cell transplantation (SCT).
- Evaluation of novel therapeutic agents and diagnostic tools.
Main Results:
- Pediatric regimens show promise for improving adult ALL outcomes.
- Advances in SCT, including reduced-intensity conditioning, expand treatment options.
- Minimal residual disease (MRD) evaluation aids risk stratification.
- New drugs like tyrosine kinase inhibitors and monoclonal antibodies offer incremental benefits.
Conclusions:
- Adapting pediatric protocols and enhancing supportive care are key to improving adult ALL outcomes.
- MRD monitoring and targeted therapies based on genetic/epigenetic understanding hold significant promise.
- Future treatments aim for more effective disease control with reduced toxicity.
Abstract:
Acute lymphoblastic leukemia (ALL) is the most frequent neoplastic disease in children, being a rare disease in adults. Many of the advances in pediatric ALL have been through modifications in the doses and schedules of available agents as opposed to the introduction of new compounds. In recent years some improvements in the outcome of ALL in adults have occurred. Application of pediatric regimens to young and middle-aged adults shows promise to improve outcome. Advances in the supportive care of patients undergoing allogeneic stem cell transplantation (SCT), the use of alternative sources of hematopoietic stem cells and the use of reduced-intensity conditioning regimens will expand the number of patients who can benefit from this therapeutic modality. The evaluation of minimal residual disease will further stratify risk classification and redefine the role of therapeutic modalities such as SCT or biologic agents. New drugs such as thyrosin kinase inhibitors or monoclonal antibodies have led to incremental improvements in outcome. Advances in the genetic and epigenetic mechanisms of the disease provide hope that targeted therapies can more effectively treat the disease with less toxicity.
Related Concept Videos
01:27Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
01:23Cells of the Adaptive Immune Response
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:16Primary Lymphoid Organs
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...